Vacuna antineumocócica. Antiguas controversias y nuevas indicaciones (I)

Archivos de Bronconeumologia

Volumn 34, Issue 6, 1998, Pages 295-299

  Miravitlles, M ^a   De Gracia, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; VACCINE;

HISTORY; HUMAN; IMMUNIZATION; IMMUNOLOGY; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BACTERIAL VACCINES; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNIZATION, SECONDARY; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 0032105109     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2896(15)30416-6     Document Type: Article

References (42)

1. Watson DA, Musher DM, Jacobson JW, Verhoef J. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. J Infect Dis 1993; 17: 913-924.
2. Heidelberger M, McLeod CM, Kaiser SJ, Robinson B. Antibody formation in volunteers following injection of pneumococci or their type-specific polysaccharides. J Exp Med 1946; 83: 303-320.
3. McLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945; 82: 445-465.
4. Pallarés R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 335: 474-480.
5. Subdirección General de Prestaciones y Evaluación de Tecnologías Sanitarias. Ministerio de Sanidad y Consumo. Informe sobre vacuna neumocócica. Med Clin (Bare) 1994; 102: 383-386.
6. García-Arenzana JM, Alcorta M, Díez de Tuesta JL, Idígoras P, Pérez-Trallero J. Indicatión de la vacuna antineumocócica en España. An Med Intern (Madr) 1993; 10: 116-118.
7. Villarubia VG, Sánchez L, Álvarez de Mon M. Las nuevas vacunas y la respuesta inmunológica (I). La memoria inmunológica. Respuesta humoral frente a respuesta celular. Med Clin (Barc) 1996; 107: 146-154.
8. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994, 154: 2.666-2.677.
9. Bruyn GAW, Zegers BJM, Van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992; 14: 251-262.
10. Virolainen A, Jero J, Käythy H, Karma P, Leinonen M, Eskola J. Nasopharyngeal antibodies to pneumococcal capsular polysaccharides in children with acute otitis media. J Infect Dis 1995; 172: 1.115-1.118.
11. Go ES, Ballas ZAK. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996; 98: 205-215.
12. Rodrigo MJ, Miravitlles M, Cruz MJ, De Gracia J, Vendrell M, Pascual C et al. Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population. Proposal for response criteria. Clin Diag Lab Immunol 1997; 4: 168-172.
13. Spika JS, Fedson DS, Facklam RR. Pneumococcal vaccination - controversies and opportunities. Infect Dis Clin North Am 1990; 4: 11-27.
14. Fedson DS, Shapiro ED, LaForce FM, Mufson MA, Musher DM, Spika JS et al. Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med 1994, 154: 2.531-2.535.
15. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech III WF. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1-6.
16. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1.453-1.460.
17. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA et al. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med 1995; 155: 2.336-2.340.
18. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993, 270: 1.826-1.831.
19. 12 levels. Ann Intern Med 1996; 124: 299-304.
20. Plans P, Garrido P, Salleras LI. Coste-efectividad de la vacunación neumocócica en Cataluña. Rev Esp Salud Pub 1995; 69: 409-417.
21. Baltussen R, Ament A, Leidl R, Van Furth R. Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands. Eur J Publ Health 1997; 7: 153-161.
22. Centers for Disease Control. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR 1993; 42: 1-18.
23. Task Force on Adult Immunization. Adult immunizations 1994. Ann Intrn Med 1994; 121: 540-541.
24. Centers for Disease Control and Prevention. Prevention of pneumococcal disease. Recommendations of the Advisory Committee of Immunization Practices (ACIP). MMWR 1997; 46: 1-24.
25. Centers for Disease Control. Pneumococcal polysaccharide vaccine usage. United States. MMWR 1984; 33: 273-286.
26. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995; 171: 885-889.
27. Mufson MA, Hughey DF, Turner CE, Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991; 9: 403-407.
28. Davidson M, Bulkow LR, Grabman J, Parkinson AJ, Chamblee C, Williams WW et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994; 154: 2.209-2.214.
29. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995; 21: 616-620.
30. McBean AM, Babish JD, Prihoda R. The utilization of pneumococcal polysaccharide vaccine among elderly medicare beneficiaries, 1985 through 1988. Arch Intern Med 1991; 151: 2.009-2.016.
31. Fedson DS. Influenzae and pneumococcal vaccination in Canada and the United States, 1980-1993: what can the two countries learn from each other? Clin Infect Dis 1995; 20: 1.371-1.376.
32. De Ramón y Casado AM, García Satúe JL, Muñoz Méndez J, Vázquez Mezquita M, Femández Francés J, González Ruiz JM et al. Situatión actual de la vacuna antineumocócica: una asignatura pendiente. Rev Clin Esp 1991; 189: 82-85.
33. Centers for Disease Control. Pneumococcal and influenza vaccination levels among adults aged > 65 years -United States, 1993. MMWR 1996; 45: 853-859.
34. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunization with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. Br Med J 1997; 314: 1.663-1.665.
35. Perry FE, Catterall JR. The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis. Thorax 1994; 49: 946-950.
36. De Velasco EA, Merkus D, Anderton S, Verheul AF, Lizzio EF, Van der Zee R et al. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugated vaccines. Infect Immun 1995; 63: 961-968.
37. Giebnik GS, Koskela M, Vella PP, Harris M, Le CT. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 1993; 167: 347-355.
38. Lu CH, Lee CJ, Kind P. Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate. Infect Immun 1994; 62: 2.754-2.760.
39. Keythy H, Ahman H, Rünnberg PR, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995; 172: 1.273-1.278.
40. Vella PP, Marburg S, Staub JM, Kniskern PJ, Miller W, Hagopian A et al. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex. Infect Immun 1992; 60: 4.977-4.983.
41. Elson CJ, Taylor RB. The suppresive effect of carrier priming on the response to a hapten-carrier conjugate. Eur J Immunol 1974, 4. 682-687.
42. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994; 265: 1.385-1.387.